CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study.
about
TLR9 expression is required for the development of cigarette smoke-induced emphysema in mice.CpG oligodeoxynucleotide nanomedicines for the prophylaxis or treatment of cancers, infectious diseases, and allergiesThe epithelial barrier and immunoglobulin A system in allergy.IgE-associated allergic disorders: recent advances in etiology, diagnosis, and treatment.Investigational new drugs for allergic rhinitis.The potential of anti-infectives and immunomodulators as therapies for asthma and asthma exacerbations.Treatment of allergic rhinitis with CpG oligodeoxynucleotides alleviates the lower airway outcomes of combined allergic rhinitis and asthma syndrome via a mechanism that possibly involves in TSLP.TH2 cell development and function.JNK-TLR9 signal pathway mediates allergic airway inflammation through suppressing melatonin biosynthesis.
P2860
Q37139546-A21706D0-A1B1-4193-BE5E-A853B8C68218Q37596126-8945202A-0EF1-4223-AE36-048D8B1CA733Q38967737-FDFD3CFA-D350-43B9-8290-491D706C15CBQ38973411-3AC1B509-146C-41F5-9E98-5A023B994C1EQ39111947-5DD15583-591C-423D-92FF-2CF5AE0F04F3Q39444008-8348F0BD-E107-4792-B9EF-3D00956B0413Q51468541-8B2E8536-CA18-4EBD-9823-5EC4DB42F36CQ52862184-83D17A2F-E3A3-420A-9F0B-622106489557Q55029792-B83E240C-78E4-4677-8026-5EF5A98F5525
P2860
CYT003, a TLR9 agonist, in persistent allergic asthma - a randomized placebo-controlled Phase 2b study.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年学术文章
@wuu
2015年学术文章
@zh
2015年学术文章
@zh-cn
2015年学术文章
@zh-hans
2015年学术文章
@zh-my
2015年学术文章
@zh-sg
2015年學術文章
@yue
2015年學術文章
@zh-hant
name
CYT003, a TLR9 agonist, in per ...... ebo-controlled Phase 2b study.
@en
CYT003, a TLR9 agonist, in per ...... ebo-controlled Phase 2b study.
@nl
type
label
CYT003, a TLR9 agonist, in per ...... ebo-controlled Phase 2b study.
@en
CYT003, a TLR9 agonist, in per ...... ebo-controlled Phase 2b study.
@nl
prefLabel
CYT003, a TLR9 agonist, in per ...... ebo-controlled Phase 2b study.
@en
CYT003, a TLR9 agonist, in per ...... ebo-controlled Phase 2b study.
@nl
P2093
P2860
P921
P356
P1433
P1476
CYT003, a TLR9 agonist, in per ...... ebo-controlled Phase 2b study.
@en
P2093
A Hammann-Haenni
C F Vogelmeier
M E Wechsler
T B Casale
P2860
P304
P356
10.1111/ALL.12663
P577
2015-06-04T00:00:00Z